Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhizophora mucronata leaf extract is a natural research compound derived from the leaves of the red mangrove plant (*Rhizophora mucronata* Lam.). It contains a diverse array of bioactive phytochemicals, including condensed tannins (such as catechin and epigallocatechin), flavonoids, alkaloids, terpenoids, and saponins. Preclinical studies have demonstrated that the extract possesses significant pharmacological potential, including anti-diarrheal, antidiabetic, anti-inflammatory, and antioxidant activities. Research has also highlighted its cytotoxic effects against various cancer cell lines, such as colon (CaCo-2), breast (MCF-7), and lung (A549) cancers, while maintaining low toxicity toward normal human cells. Historically, it has been utilized in traditional folk medicine across regions like India and China for treating gastrointestinal disorders, fever, and angina. It is currently not a commercially developed pharmaceutical drug and remains in the preclinical research phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhizophora mucronata leaf extract.